{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:04:58Z","timestamp":1782453898859,"version":"3.54.5"},"reference-count":18,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2013,11,13]]},"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical and microbiological efficacy and safety of three doses of 3\u2005g fosfomycin tromethamine administered orally to treat lower urinary tract infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and participants<\/jats:title>\n                    <jats:p>This prospective, uncontrolled, open-label study was conducted in 12 medical centres in China, between January and December 2011. According to the diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18\u201370\u2005years) with acute uncomplicated cystitis, recurrent lower urinary tract infection or complicated lower urinary tract infection received three doses of 3\u2005g fosfomycin tromethamine orally, at days 1, 3 and 5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Efficacy endpoints (clinical efficacy, microbiological efficacy and overall efficacy) were evaluated on day 15. Clinical symptoms, physical signs, urinalysis, liver and kidney function, patient records and evaluation of adverse events (AEs) and serious AEs up to day 15 were evaluated for analysis of safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>361 patients were included in the full analysis set, 356 in the safety analysis set and 335 in the per-protocol set (PPS). In the PPS, the clinical efficacy rates at day 15 for acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary tract infection were 94.71% (179\/189), 77.22% (61\/79) and 62.69% (42\/67), respectively. The microbiological efficacy rates (day 15) were 97.65% (83\/85), 94.44% (34\/36) and 83.87% (26\/31), respectively. The overall efficacy rates (day 15) were 95.29% (81\/85), 77.78% (28\/36) and 64.52% (20\/31), respectively. 20\/356 (5.6%) patients reported drug-related AEs, the most common being diarrhoea. No serious drug-related AEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This fosfomycin tromethamine dosing regimen showed clinical and microbiological efficacy with some AEs and good tolerability in patients with acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary tract infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-004157","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T20:16:51Z","timestamp":1386274611000},"page":"e004157","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study"],"prefix":"10.1136","volume":"3","author":[{"given":"Lu-Dong","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Urology, Beijing Tongren Hospital Capital Medical University, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Tongren Hospital Capital Medical University, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Cancer Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Feng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Shougang Hospital (Wu Jieping Urology Center), Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Jie","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Kang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, Qilu Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Wuhan Hubei Tongji Hospital, Wuhan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Kun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Province Xiangya Second Hospital, Changsha, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai Changhai Hospital, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongda Hospital Southeast University, Nanjing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"key":"2025121509443141000_3.12.e004157.1","doi-asserted-by":"publisher","DOI":"10.1067\/mda.2003.7"},{"key":"2025121509443141000_3.12.e004157.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530270029027"},{"key":"2025121509443141000_3.12.e004157.3","first-page":"19","article-title":"Nosocomial infection point-prevalence survey in three consecutive years","volume":"01","author":"Wang","year":"2006","journal-title":"Chin J Infect Control"},{"key":"2025121509443141000_3.12.e004157.4","first-page":"1119","article-title":"A nosocomial infection point-prevalence survey: results and analysis","volume":"10","author":"Wang","year":"2005","journal-title":"Chin J Nosocomiol"},{"key":"2025121509443141000_3.12.e004157.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00231-0"},{"key":"2025121509443141000_3.12.e004157.6","first-page":"734","article-title":"Results analysis of ESBLs-producing E. coli in vitro susceptibility to fosfomycin","volume":"10","author":"Qi","year":"2010","journal-title":"China Trop Med"},{"key":"2025121509443141000_3.12.e004157.7","first-page":"577","article-title":"In vitro antimicrobial activity of fosfomycin against Gram-negative bacilli","volume":"32","author":"Da","year":"2010","journal-title":"Dalian Med Univ"},{"key":"2025121509443141000_3.12.e004157.8","unstructured":"Na YQ Sun G . Guidelines for diagnosis and treatment of urological diseases in China, 2009. Beijing: People's Health Publishing House, 2009:643\u20134."},{"key":"2025121509443141000_3.12.e004157.9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00007"},{"key":"2025121509443141000_3.12.e004157.10","unstructured":"Grabe M Bjerklund-Johansen TE Botto H . European Association of Urology, Guidelines on Urological Infections. 2010. http:\/\/www.uroweb.org\/"},{"key":"2025121509443141000_3.12.e004157.11","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17227"},{"key":"2025121509443141000_3.12.e004157.12","first-page":"247","article-title":"Analysis of risk factors about ESBLs-producing E. coli urinary tract infection","volume":"21","author":"Qiao","year":"2011","journal-title":"J Hosp Infect"},{"key":"2025121509443141000_3.12.e004157.13","first-page":"23","article-title":"Comparative study of antibiotic resistance in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta lactamases","volume":"23","author":"Kong","year":"2000","journal-title":"J Lab Med"},{"key":"2025121509443141000_3.12.e004157.14","first-page":"586","article-title":"2006\u20132007 Mohnarin report: bacterial distribution and resistance in urinary tract infections","volume":"33","author":"Gao","year":"2008","journal-title":"Chin J Antibiot"},{"key":"2025121509443141000_3.12.e004157.15","first-page":"34","article-title":"Relationship between antimicrobial treatment and imbalance of intestinal flora in the elders","volume":"9","author":"Chen","year":"2007","journal-title":"Pract Clin Med"},{"key":"2025121509443141000_3.12.e004157.16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3906\/sag-1210-75","article-title":"Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004\u20132011","volume":"43","author":"Pullukcu","year":"2013","journal-title":"Turk J Med Sci"},{"key":"2025121509443141000_3.12.e004157.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.039"},{"key":"2025121509443141000_3.12.e004157.18","doi-asserted-by":"publisher","DOI":"10.1007\/BF01710021"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-004157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:44:39Z","timestamp":1765820679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-004157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,4]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/bmjopen-2013-004157"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-004157","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}